Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vojislav Pejović
Observed names:
V. Pejovic,
Vojislav Pejovic
Institution:
Prescott College
Observed institutions:
Tulane University,
Johannes Gutenberg University Mainz,
Tulane Medical Center,
Prescott College,
University of Belgrade,
Institute of Chemistry, Technology and Metallurgy,
Institute for Biological Research “Siniša Stanković”,
University of Tübingen
show all 8
OpenAlex ID:
A5036745592
The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors
2013
·
George T. Grossberg
, Facundo Manes
, et al.
·
CNS Drugs
·
174
PDF
Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations
2008
·
Martin R. Farlow
, Michael L. Miller
, et al.
·
Dementia and Geriatric Cognitive Disorders
·
158
Increased Apoptosis in Cystinotic Fibroblasts and Renal Proximal Tubule Epithelial Cells Results from Cysteinylation of Protein Kinase Cδ
2006
·
Margaret A. Park
, Vojislav Pejovic
, et al.
·
Journal of the American Society of Nephrology
·
86
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
2015
·
Alireza Atri
, Suzanne B Hendrix
, et al.
·
Alzheimer s Research & Therapy
·
80
PDF
Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer’s Disease
2009
·
George T. Grossberg
, Vojislav Pejović
, et al.
·
Dementia and Geriatric Cognitive Disorders
·
65
Expression and Renaturation of the N-terminal Extracellular Domain of Torpedo Nicotinic Acetylcholine Receptor α-Subunit
1998
·
André Schrattenholz
, Sascha Pfeiffer
, et al.
·
Journal of Biological Chemistry
·
45
PDF
Modulation of feeding‐related peptide/protein signals by the blood–brain barrier
2004
·
Weihong Pan
, Victoria Akerstrom
, et al.
·
Journal of Neurochemistry
·
40
Memantine and Functional Communication in Alzheimer's Disease: Results of a 12-Week, International, Randomized Clinical Trial
2012
·
Judith Saxton
, Robert K. Hofbauer
, et al.
·
Journal of Alzheimer s Disease
·
29
PDF
Effects of memantine treatment on language abilities and functional communication: A review of data
2013
·
Michael Tocco
, Kathryn Bayles
, et al.
·
Aphasiology
·
18
Memantine Discontinuation and the Health Status of Nursing Home Residents With Alzheimer's Disease
2010
·
Howard Fillit
, Robert K. Hofbauer
, et al.
·
Journal of the American Medical Directors Association
·
17
Integrative Proteomics: Functional and Molecular Characterization of a Particular Glutamate-Related Neuregulin Isoform
2005
·
Simone Schillo
, Vojislav Pejović
, et al.
·
Journal of Proteome Research
·
14
Brain proteome of mice lacking the receptors for tumor necrosis factor α
2004
·
Vojislav Pejović
, Vukić Šoškić
, et al.
·
PROTEOMICS
·
13
Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I–II hypertension
2012
·
F. Wilford Germino
, Yuhua Lin
, et al.
·
Therapeutic Advances in Cardiovascular Disease
·
12
P4‐352: Area Under the Curve (auc) Pooled Analysis of Four Randomized Clinical Trials Shows Cumulative Benefits of Memantine‐donepezil Combination Over Component Monotherapies Across Clinical Domains in Alzheimer's Dementia
2014
·
Alireza Atri
, Suzanne Hendrix
, et al.
·
Alzheimer s & Dementia
·
4
P1‐370: Efficacy and Tolerability of Memantine Extended Release Added to Stable Donepezil Regimen in Individuals With Moderate to Severe Alzheimer's Disease: Subset Analysis of a Randomized Clinical Trial
2014
·
George Grossberg
, Gustavo Alva
, et al.
·
Alzheimer s & Dementia
·
4
P3‐386: Response across multiple outcome measures in a randomized trial of extended‐release memantine (28 mg, once daily) in patients with moderate‐to‐severe Alzheimer's disease
2012
·
Stephen Graham
, Suzanne Hendrix
, et al.
·
Alzheimer s & Dementia
·
4
Adding Memantine to Stable Cholinesterase Inhibitor Therapy in Patients with Moderate to Severe Alzheimer’s Disease is Associated with Improvement in Various Neuropsychiatric Symptoms: A Pooled Analysis (P7.106)
2015
·
Gustavo Alva
, Noel Ellison
, et al.
·
Neurology
·
3
P3‐299: Caregiver distress related to neuropsychiatric symptoms is reduced with extended‐release memantine‐cholinesterase inhibitor combination in patients with moderate to severe Alzheimer's disease
2015
·
Alireza Atri
, Suzanne Hendrix
, et al.
·
Alzheimer s & Dementia
·
2
PDF
Efficacy and Tolerability of Memantine Extended Release Added to Stable Donepezil Regimen in Individuals with Moderate to Severe Alzheimer’s Disease: Subset Analysis of a Randomized Clinical Trial (P7.101)
2015
·
George Grossberg
, Gustavo Alva
, et al.
·
Neurology
·
2
Extended-Release Daily Memantine Provides Increasing Cumulative Benefits Across Clinical Domains Over 24 Weeks in Patients With Moderate to Severe Alzheimer’s Disease: An Analysis of Area Under the Curve (P1.006)
2014
·
Alireza Atri
, Suzanne Hendrix
, et al.
·
Neurology
·
2
Cumulative Benefits of Extended-Release Memantine (28 mg, Once Daily) Across Clinical Domains in Patients With Moderate to Severe Alzheimer's Disease: An Area Under the Curve Analysis
2014
·
Alireza Atri
, Michael Tocco
, et al.
·
American Journal of Geriatric Psychiatry
·
2
P3–271: Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial
2013
·
Michael Tocco
, Suzanne Hendrix
, et al.
·
Alzheimer s & Dementia
·
2
Extended-Release Memantine (28 mg, Once Daily) Provides Behavioral Benefits Across a Wide Range of Disease Severity in Patients With Moderate to Severe Alzheimer's Disease: Post Hoc Analysis From a Randomized Trial
2013
·
Stephen M. Graham
, Suzanne Hendrix
, et al.
·
American Journal of Geriatric Psychiatry
·
2
P3‐380: Effects of extended‐release memantine (28 mg, once daily) on language and communication abilities in a randomized trial of patients with moderate‐to‐severe Alzheimer's disease
2012
·
Michael Tocco
, Suzanne Hendrix
, et al.
·
Alzheimer s & Dementia
·
2
Extended-Release Memantine (28 mg, Once Daily) and Sustained Behavioral Improvement: Post Hoc Responder Analysis from a Randomized Trial in Patients with Moderate to Severe Alzheimer's Disease (P04.197)
2012
·
J. Cummings
, S. Hendrix
, et al.
·
Neurology
·
2
Show more works
View as search
Works count:
36
Citation count:
792
H-index:
12
I10-index:
13
Year
Topic
Type